Growth hormone treatment of short children born small for gestational age

Growth responses with continuous and discontinuous regimens over 6 years

Francis De Zegher, Kerstin Albertsson-Wikland, Hartmut A. Wollmann, Pierre Chatelain, Jean Louis Chaussain, Annika Löfströ, Björn Jonsson, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

We report an epi-analysis of 6-yr growth responses obtained with GH treatment in short children born small for gestational age (SGA). Four randomized, multicenter studies explored the effects of continuous and discontinuous regimens of GH treatment in short, non-GH-deficient SGA children. A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively. At the start of the study, the age of these 188 children averaged 5.2 yr (range, 2-8 yr), height was -3.4 SD score, and height adjusted for parental height was -2.4 SD score. Onset of puberty was observed in 46% of the GH-treated cohort, on the average, at 10.7 yr in girls and 11.7 yr in boys. Two studies essentially investigated the effects of continuous GH treatment at a dose of 33 or 67 μg/kg·day, and two studies focused on the growth characteristics during an initial GH treatment for 2-3 yr (dose range, 33-100 μg/kg·day), followed by a withdrawal phase of 1-2 yr, and then by either no or i or more episodes of further GH treatment (33 or 67 μg/kg·day). Continuous GH treatment for 6 yr resulted in height increments of 2.0 ± 0.2 SD (33 μg/kg·day; n = 35) and 2.7 ± 0.2 SD (67 μg/kg·day; n = 27). Discontinuous GH treatment was given to 77 children, most of them experiencing only 1 (n = 47) or 2 (n = 26) treatment phases with an average duration of 2.0 yr. All these children received GH during the first 2 yr; the dose was only 32 μg/kg·day when averaged over 6 yr. Some individualization of treatment schedules was allowed, and the majority of investigators seemed to aim for a low normal height level, adjusted for parental height. After 2 yr, the mean adjusted height SD score had increased to -0.4 ± 0.1 and stabilized thereafter. Bone maturation progressed similarly in all treatment subgroups, and after 6 yr of study, bone age remained slightly delayed compared to chronological age. Multivariate analysis identified the average GH dose over 6 yr, parental-adjusted height SD score, and age at start as prime predictors of the growth response. GH treatment was well tolerated. In conclusion, this epi-analysis of growth responses over 6 yr confirms the administration of GH as an effective approach to normalize the stature of short, non-GH-deficient SGA children, at least during childhood and early puberty. In addition, it is now increasingly apparent that a relatively broad spectrum of GH regimens is effective, and this experience should facilitate the design of more individualized treatment schedules in the future, in particular for young children.

Original languageEnglish (US)
Pages (from-to)2816-2821
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume85
Issue number8
DOIs
StatePublished - 2000

Fingerprint

Growth Hormone
Gestational Age
Growth
Bone
Therapeutics
Puberty
Appointments and Schedules
Bone and Bones
Multicenter Studies
Multivariate Analysis
Research Personnel

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

De Zegher, F., Albertsson-Wikland, K., Wollmann, H. A., Chatelain, P., Chaussain, J. L., Löfströ, A., ... Rosenfeld, R. R. (2000). Growth hormone treatment of short children born small for gestational age: Growth responses with continuous and discontinuous regimens over 6 years. Journal of Clinical Endocrinology and Metabolism, 85(8), 2816-2821. https://doi.org/10.1210/jc.85.8.2816

Growth hormone treatment of short children born small for gestational age : Growth responses with continuous and discontinuous regimens over 6 years. / De Zegher, Francis; Albertsson-Wikland, Kerstin; Wollmann, Hartmut A.; Chatelain, Pierre; Chaussain, Jean Louis; Löfströ, Annika; Jonsson, Björn; Rosenfeld, Ronald (Ron).

In: Journal of Clinical Endocrinology and Metabolism, Vol. 85, No. 8, 2000, p. 2816-2821.

Research output: Contribution to journalArticle

De Zegher, F, Albertsson-Wikland, K, Wollmann, HA, Chatelain, P, Chaussain, JL, Löfströ, A, Jonsson, B & Rosenfeld, RR 2000, 'Growth hormone treatment of short children born small for gestational age: Growth responses with continuous and discontinuous regimens over 6 years', Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 8, pp. 2816-2821. https://doi.org/10.1210/jc.85.8.2816
De Zegher, Francis ; Albertsson-Wikland, Kerstin ; Wollmann, Hartmut A. ; Chatelain, Pierre ; Chaussain, Jean Louis ; Löfströ, Annika ; Jonsson, Björn ; Rosenfeld, Ronald (Ron). / Growth hormone treatment of short children born small for gestational age : Growth responses with continuous and discontinuous regimens over 6 years. In: Journal of Clinical Endocrinology and Metabolism. 2000 ; Vol. 85, No. 8. pp. 2816-2821.
@article{24a3df27a6a845519f2be233c99066bf,
title = "Growth hormone treatment of short children born small for gestational age: Growth responses with continuous and discontinuous regimens over 6 years",
abstract = "We report an epi-analysis of 6-yr growth responses obtained with GH treatment in short children born small for gestational age (SGA). Four randomized, multicenter studies explored the effects of continuous and discontinuous regimens of GH treatment in short, non-GH-deficient SGA children. A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively. At the start of the study, the age of these 188 children averaged 5.2 yr (range, 2-8 yr), height was -3.4 SD score, and height adjusted for parental height was -2.4 SD score. Onset of puberty was observed in 46{\%} of the GH-treated cohort, on the average, at 10.7 yr in girls and 11.7 yr in boys. Two studies essentially investigated the effects of continuous GH treatment at a dose of 33 or 67 μg/kg·day, and two studies focused on the growth characteristics during an initial GH treatment for 2-3 yr (dose range, 33-100 μg/kg·day), followed by a withdrawal phase of 1-2 yr, and then by either no or i or more episodes of further GH treatment (33 or 67 μg/kg·day). Continuous GH treatment for 6 yr resulted in height increments of 2.0 ± 0.2 SD (33 μg/kg·day; n = 35) and 2.7 ± 0.2 SD (67 μg/kg·day; n = 27). Discontinuous GH treatment was given to 77 children, most of them experiencing only 1 (n = 47) or 2 (n = 26) treatment phases with an average duration of 2.0 yr. All these children received GH during the first 2 yr; the dose was only 32 μg/kg·day when averaged over 6 yr. Some individualization of treatment schedules was allowed, and the majority of investigators seemed to aim for a low normal height level, adjusted for parental height. After 2 yr, the mean adjusted height SD score had increased to -0.4 ± 0.1 and stabilized thereafter. Bone maturation progressed similarly in all treatment subgroups, and after 6 yr of study, bone age remained slightly delayed compared to chronological age. Multivariate analysis identified the average GH dose over 6 yr, parental-adjusted height SD score, and age at start as prime predictors of the growth response. GH treatment was well tolerated. In conclusion, this epi-analysis of growth responses over 6 yr confirms the administration of GH as an effective approach to normalize the stature of short, non-GH-deficient SGA children, at least during childhood and early puberty. In addition, it is now increasingly apparent that a relatively broad spectrum of GH regimens is effective, and this experience should facilitate the design of more individualized treatment schedules in the future, in particular for young children.",
author = "{De Zegher}, Francis and Kerstin Albertsson-Wikland and Wollmann, {Hartmut A.} and Pierre Chatelain and Chaussain, {Jean Louis} and Annika L{\"o}fstr{\"o} and Bj{\"o}rn Jonsson and Rosenfeld, {Ronald (Ron)}",
year = "2000",
doi = "10.1210/jc.85.8.2816",
language = "English (US)",
volume = "85",
pages = "2816--2821",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Growth hormone treatment of short children born small for gestational age

T2 - Growth responses with continuous and discontinuous regimens over 6 years

AU - De Zegher, Francis

AU - Albertsson-Wikland, Kerstin

AU - Wollmann, Hartmut A.

AU - Chatelain, Pierre

AU - Chaussain, Jean Louis

AU - Löfströ, Annika

AU - Jonsson, Björn

AU - Rosenfeld, Ronald (Ron)

PY - 2000

Y1 - 2000

N2 - We report an epi-analysis of 6-yr growth responses obtained with GH treatment in short children born small for gestational age (SGA). Four randomized, multicenter studies explored the effects of continuous and discontinuous regimens of GH treatment in short, non-GH-deficient SGA children. A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively. At the start of the study, the age of these 188 children averaged 5.2 yr (range, 2-8 yr), height was -3.4 SD score, and height adjusted for parental height was -2.4 SD score. Onset of puberty was observed in 46% of the GH-treated cohort, on the average, at 10.7 yr in girls and 11.7 yr in boys. Two studies essentially investigated the effects of continuous GH treatment at a dose of 33 or 67 μg/kg·day, and two studies focused on the growth characteristics during an initial GH treatment for 2-3 yr (dose range, 33-100 μg/kg·day), followed by a withdrawal phase of 1-2 yr, and then by either no or i or more episodes of further GH treatment (33 or 67 μg/kg·day). Continuous GH treatment for 6 yr resulted in height increments of 2.0 ± 0.2 SD (33 μg/kg·day; n = 35) and 2.7 ± 0.2 SD (67 μg/kg·day; n = 27). Discontinuous GH treatment was given to 77 children, most of them experiencing only 1 (n = 47) or 2 (n = 26) treatment phases with an average duration of 2.0 yr. All these children received GH during the first 2 yr; the dose was only 32 μg/kg·day when averaged over 6 yr. Some individualization of treatment schedules was allowed, and the majority of investigators seemed to aim for a low normal height level, adjusted for parental height. After 2 yr, the mean adjusted height SD score had increased to -0.4 ± 0.1 and stabilized thereafter. Bone maturation progressed similarly in all treatment subgroups, and after 6 yr of study, bone age remained slightly delayed compared to chronological age. Multivariate analysis identified the average GH dose over 6 yr, parental-adjusted height SD score, and age at start as prime predictors of the growth response. GH treatment was well tolerated. In conclusion, this epi-analysis of growth responses over 6 yr confirms the administration of GH as an effective approach to normalize the stature of short, non-GH-deficient SGA children, at least during childhood and early puberty. In addition, it is now increasingly apparent that a relatively broad spectrum of GH regimens is effective, and this experience should facilitate the design of more individualized treatment schedules in the future, in particular for young children.

AB - We report an epi-analysis of 6-yr growth responses obtained with GH treatment in short children born small for gestational age (SGA). Four randomized, multicenter studies explored the effects of continuous and discontinuous regimens of GH treatment in short, non-GH-deficient SGA children. A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively. At the start of the study, the age of these 188 children averaged 5.2 yr (range, 2-8 yr), height was -3.4 SD score, and height adjusted for parental height was -2.4 SD score. Onset of puberty was observed in 46% of the GH-treated cohort, on the average, at 10.7 yr in girls and 11.7 yr in boys. Two studies essentially investigated the effects of continuous GH treatment at a dose of 33 or 67 μg/kg·day, and two studies focused on the growth characteristics during an initial GH treatment for 2-3 yr (dose range, 33-100 μg/kg·day), followed by a withdrawal phase of 1-2 yr, and then by either no or i or more episodes of further GH treatment (33 or 67 μg/kg·day). Continuous GH treatment for 6 yr resulted in height increments of 2.0 ± 0.2 SD (33 μg/kg·day; n = 35) and 2.7 ± 0.2 SD (67 μg/kg·day; n = 27). Discontinuous GH treatment was given to 77 children, most of them experiencing only 1 (n = 47) or 2 (n = 26) treatment phases with an average duration of 2.0 yr. All these children received GH during the first 2 yr; the dose was only 32 μg/kg·day when averaged over 6 yr. Some individualization of treatment schedules was allowed, and the majority of investigators seemed to aim for a low normal height level, adjusted for parental height. After 2 yr, the mean adjusted height SD score had increased to -0.4 ± 0.1 and stabilized thereafter. Bone maturation progressed similarly in all treatment subgroups, and after 6 yr of study, bone age remained slightly delayed compared to chronological age. Multivariate analysis identified the average GH dose over 6 yr, parental-adjusted height SD score, and age at start as prime predictors of the growth response. GH treatment was well tolerated. In conclusion, this epi-analysis of growth responses over 6 yr confirms the administration of GH as an effective approach to normalize the stature of short, non-GH-deficient SGA children, at least during childhood and early puberty. In addition, it is now increasingly apparent that a relatively broad spectrum of GH regimens is effective, and this experience should facilitate the design of more individualized treatment schedules in the future, in particular for young children.

UR - http://www.scopus.com/inward/record.url?scp=0034458088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034458088&partnerID=8YFLogxK

U2 - 10.1210/jc.85.8.2816

DO - 10.1210/jc.85.8.2816

M3 - Article

VL - 85

SP - 2816

EP - 2821

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -